ABBV vs INTU: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intuit Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Intuit Inc. · Technology
$277.13
+25.3% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
INTU has more upside to fair value
(+25.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
INTU |
| Current Price |
$261.70 |
$277.13 |
| Fair Value Estimate |
$259.04 |
$347.25 |
| Upside to Fair Value |
-1.0%
|
+25.3%
|
| Market Cap |
$462.4B |
$75.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
11.0x
|
| Price / Sales |
7.2x
|
3.5x
|
| Price / FCF |
23.6x
|
8.8x
|
| Revenue Growth YoY |
+10.2%
|
+13.7%
|
| Gross Margin |
71.5%
|
80.9%
|
| Operating Margin |
29.3%
|
28.8%
|
| Return on Equity |
-136.5%
|
23.4%
|
| Dividend Yield |
2.61% |
1.73% |
| FCF Yield |
4.25%
|
11.43%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Intuit is a financial management software platform serving small and mid-market businesses through QuickBooks, consumers through TurboTax, and consumers through Credit Karma, with a professional tax segment in Lacerte, ProSeries and ProConnect. The business quality is high on fundamentals: TTM gross margin of 80.9%, TTM operating margin of 28.8%, TTM net margin of 21.3%, ROE of 23.4%, and free ca…
Accumulation Zones
| Metric |
ABBV |
INTU |
| Zone Low |
$194.28 |
$260.44 |
| Zone High |
$220.18 |
$295.16 |
| In Buy Zone? |
No
|
Yes
|